Preclinical Development of an Anti-NaPi2b (<i>SLC34A2</i>) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers - Concepedia

Concepedia

Publication | Closed Access

Preclinical Development of an Anti-NaPi2b (<i>SLC34A2</i>) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers

78

Citations

28

References

2015

Year

Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric B. Harstad, Leslie Roth, Siao Ping Tsai, Melissa M. Schutten, Keyang Xu, Maria Hristopoulos,

Clinical Cancer Research

Abstract

Overall, our preclinical results suggest that the ADC targeting NaPi2b provides an effective new therapy for the treatment of NSCLC and ovarian cancer and is currently undergoing clinical developments.

References

	Year	Citations

Page 1